Skip to main content

Table 4 AHP results- normalized matrix

From: Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

MCDA criteria

Indication uniqueness

Disease rarity

Disease severity

Adv.tech.

Manufacturing technology

Therapeutic alternative

Sci. evid. Clin.eff

Benefits from use of medicine (safety aspects)

Cost effectiveness analysis

Budget impact analysis

Therapy cost

HTA recommendations issued elsewhere

Rationalization analysis

Weight

Indication uniqueness

0.024540349

0.014020913

0.014608234

0.014867258

0.014915032

0.015760303

0.017901509

0.020706096

0.023441153

0.026396161

0.031745601

0.03841396

0.042687007

2.31%

Disease rarity

0.058466036

0.033404057

0.019141824

0.019481235

0.019543835

0.020651432

0.023457149

0.027132126

0.030715994

0.034588072

0.041597684

0.050335534

0.055934698

3.34%

Disease severity

0.053850296

0.055939809

0.032055685

0.017943243

0.018000901

0.019021056

0.021605269

0.024990116

0.028291047

0.031857435

0.038313656

0.046361676

0.051518801

3.38%

Adv.tech.

0.00615432

0.006393121

0.006660922

0.003728466

0.002057246

0.002173835

0.002469174

0.002856013

0.003233263

0.00364085

0.004378704

0.005298477

0.005887863

0.42%

Manufacturing technology

0.00307716

0.003196561

0.003330461

0.003389515

0.001870223

0.001086917

0.001234587

0.001428007

0.001616631

0.001820425

0.002189352

0.002649239

0.002943931

0.23%

Therapeutic alternative

0.106162012

0.110281337

0.114900898

0.116938252

0.117314019

0.068179368

0.042593244

0.049266229

0.055773779

0.062804658

0.075532637

0.091398732

0.101565636

8.56%

Sci. evid. Clin.eff

0.169243788

0.175810828

0.183175345

0.1864233

0.187022349

0.197621357

0.12345868

0.078540365

0.088914719

0.100123368

0.120414348

0.145708124

0.161916232

14.76%

Benefits from use of medicine (safety aspects)

0.13385645

0.139050382

0.144875045

0.147443882

0.147917676

0.156300528

0.177535622

0.112942343

0.07032346

0.079188482

0.095236803

0.11524188

0.12806102

12.68%

Cost effectiveness analysis

0.095391953

0.099093376

0.103244285

0.105074951

0.105412597

0.111386583

0.126519639

0.146341176

0.091119217

0.056433171

0.067869905

0.082126397

0.091261876

9.86%

Budget impact analysis

0.090776214

0.094298535

0.098248594

0.099990679

0.100311987

0.10599691

0.120397721

0.139260151

0.157654949

0.09764097

0.064585878

0.078152539

0.086845979

10.26%

Therapy cost

0.14154935

0.147041783

0.153201197

0.155917669

0.156418692

0.165283317

0.187738819

0.217151422

0.245834836

0.276824938

0.183109422

0.121864976

0.135420848

17.60%

HTA recommendations issued elsewhere

0.086160474

0.089503694

0.093252903

0.094906407

0.095211378

0.100607237

0.114275803

0.132179126

0.149638596

0.168502136

0.202650744

0.13487033

0.082430082

11.88%

Rationalization analysis

0.030771598

0.031965605

0.033304608

0.033895145

0.034004063

0.035931156

0.040812787

0.047206831

0.053442356

0.060179334

0.072375266

0.087578136

0.053526027

4.73%

SUM

1

1

1

1

1

1

1

1

1

1

1

1

1

100.00%

  1. Sci. evid. clin.eff Scientific evidence for clinical efficiency, Adv.tech. Advancement of technology